Antisense inhibition of phosphodiesterase expression

被引:7
作者
Epstein, PM [1 ]
机构
[1] Univ Connecticut, Ctr Hlth, Dept Pharmacol, Farmington, CT 06030 USA
关键词
D O I
10.1006/meth.1997.0562
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Cyclic nucleotide phosphodiesterases (PDEs) are represented by a superfamily of structurally and functionally related enzymes of which more than 30 different forms have so far been identified and grouped into seven broad gene families, some of which contain multiple genes and many splice variants, within a given gene family. Since all of the forms of PDE have the potential to regulate levels of the second messenger, cAMP or cGMP, and some of the forms appear to be tissue specific in their expression and differentially regulated, it would be useful to be able to selectively inhibit a given form of PDE, to study the physiological consequences of this inhibition, with the intent of possible therapeutic application. While gene family-specific pharmacological inhibitors exist for six of the seven gene families, none of these inhibitors is yet capable of distinguishing PDE members within a given gene family in its inhibition. One approach to selectively inhibit a specific form of PDE, without affecting others, is through use of antisense oligonucleotides to block the expression of a given PDE form. This article describes ways to optimally develop and test antisense oligonucleotides to inhibit expression of PDE. (C) 1998 Academic Press.
引用
收藏
页码:21 / 33
页数:13
相关论文
共 72 条
[1]   Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies [J].
Agrawal, S ;
Jiang, ZW ;
Zhao, QY ;
Shaw, D ;
Cai, QY ;
Roskey, A ;
Channavajjala, L ;
Saxinger, C ;
Zhang, RW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (06) :2620-2625
[2]   Antisense oligonucleotides: Towards clinical trials [J].
Agrawal, S .
TRENDS IN BIOTECHNOLOGY, 1996, 14 (10) :376-387
[3]   In vivo studies with antisense oligonucleotides [J].
Akhtar, S ;
Agrawal, S .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1997, 18 (01) :12-18
[4]   Second-generation antisense oligonucleotides: Structure-activity relationships and the design of improved signal-transduction inhibitors [J].
Altmann, KH ;
Fabbro, D ;
Dean, NM ;
Geiger, T ;
Monia, BP ;
Muller, M ;
Nicklin, P .
BIOCHEMICAL SOCIETY TRANSACTIONS, 1996, 24 (03) :630-637
[5]  
BEAVO JA, 1994, MOL PHARMACOL, V46, P399
[6]   PRIMARY SEQUENCE OF CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE ISOZYMES AND THE DESIGN OF SELECTIVE INHIBITORS [J].
BEAVO, JA ;
REIFSNYDER, DH .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (04) :150-155
[7]   CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES - FUNCTIONAL IMPLICATIONS OF MULTIPLE ISOFORMS [J].
BEAVO, JA .
PHYSIOLOGICAL REVIEWS, 1995, 75 (04) :725-748
[8]   BINDING, UPTAKE, AND INTRACELLULAR TRAFFICKING OF PHOSPHOROTHIOATE-MODIFIED OLIGODEOXYNUCLEOTIDES [J].
BELTINGER, C ;
SARAGOVI, HU ;
SMITH, RM ;
LESAUTEUR, L ;
SHAH, N ;
DEDIONISIO, L ;
CHRISTENSEN, L ;
RAIBLE, A ;
JARETT, L ;
GEWIRTZ, AM .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (04) :1814-1823
[9]  
Bennett C F, 1994, Adv Pharmacol, V28, P1, DOI 10.1016/S1054-3589(08)60492-5
[10]  
BENNETT CF, 1992, MOL PHARMACOL, V41, P1023